Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator's choice of endocrine monotherapy for ER+/HER2-advanced/ metastatic breast cancer (mBC).

This article has no abstract
Epistemonikos ID: d3f15bc8efcdeea01ddbc3a62c6394dd08da3baa
First added on: Feb 15, 2025